Citation

Kurzthaler I, Bodner T, Kemmler G, Entner T, Wissel J, Berger T, Fleischhacker WW. Hum. Psychopharmacol. 2005; 20(4): 291-293.

Affiliation

Department of Biological Psychiatry, Innsbruck University Clinics, Austria. ilsemarie.kurzthaler@uibk.ac.at

Copyright

(Copyright © 2005, John Wiley and Sons)

DOI

10.1002/hup.688

PMID

15834843

Abstract

The primary goal of this prospective extended case series was to obtain the first data about the potential influence of nabilone intake on driving ability related neuropsychological functions. Six patients were investigated within a placebo controlled, double-blind crossover study of this synthetic cannabinoid (2 mg/day) in patients with multiple sclerosis and spasticity associated pain. Five neuropsychological functions (reaction time, working memory, divided attention, psychomotor speed and mental flexibility) were assessed.No indication was found of a deterioration of any of the five investigated neuropsychological functions during the 4-week treatment period with nabilone.